Biopharma financing remains robust in 2025 with notable increases in seed and Series A investments despite fewer contributing companies. GenesisM has initiated construction of a 154,000 sq ft biomanufacturing facility in the Greater Boston area, a critical addition to the nation's leading biopharma cluster. Asian capital flows continue strong with Ascentage Pharma raising $192 million in Hong Kong. Meanwhile, various public and private financings have taken place across med-tech and biotech sectors this month, reflecting ongoing investor confidence amidst industry shifts.